# An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

> **NCT05097131** · — · TERMINATED · sponsor: **Biogen** · enrollment: 29 (actual)

## Conditions studied

- Alzheimers Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05097131
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-18
- **Primary completion:** 2022-05-20
- **Final completion:** 2022-05-20
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** As a result of the national policy for coverage, it is expected there will be limited aducanumab-avwa prescription and usage in routine clinical practice making the study not feasible for enrollment.
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05097131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05097131, "An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05097131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*